Publikationen in Zusammenarbeit mit Forschern von Fondazione IRCCS Istituto Nazionale dei Tumori (1)

2018

  1. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

    The Lancet Oncology, Vol. 19, Núm. 4, pp. 521-536